And with the development of molecular targeted therapies and immunotherapies, VEGFR-2 inhibitors and PD-1 antibodies could also provide a good choice for the treatment of gastric carcinoma with HER-2 negative status.[26–28] The optimal management strategy of this kind of metastasis from gastric cancer still needs further investigation because of limited data. This evidence concerns the gene KDR and gastric cancer.